1. Home
  2. AGAE vs RNLX Comparison

AGAE vs RNLX Comparison

Compare AGAE & RNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGAE
  • RNLX
  • Stock Information
  • Founded
  • AGAE 2017
  • RNLX 2018
  • Country
  • AGAE United States
  • RNLX United States
  • Employees
  • AGAE N/A
  • RNLX N/A
  • Industry
  • AGAE Cable & Other Pay Television Services
  • RNLX Medical Specialities
  • Sector
  • AGAE Telecommunications
  • RNLX Health Care
  • Exchange
  • AGAE Nasdaq
  • RNLX Nasdaq
  • Market Cap
  • AGAE 33.7M
  • RNLX 32.8M
  • IPO Year
  • AGAE N/A
  • RNLX 2020
  • Fundamental
  • Price
  • AGAE $1.36
  • RNLX $0.29
  • Analyst Decision
  • AGAE
  • RNLX
  • Analyst Count
  • AGAE 0
  • RNLX 0
  • Target Price
  • AGAE N/A
  • RNLX N/A
  • AVG Volume (30 Days)
  • AGAE 238.9K
  • RNLX 5.0M
  • Earning Date
  • AGAE 08-08-2024
  • RNLX 05-15-2024
  • Dividend Yield
  • AGAE N/A
  • RNLX N/A
  • EPS Growth
  • AGAE N/A
  • RNLX N/A
  • EPS
  • AGAE N/A
  • RNLX N/A
  • Revenue
  • AGAE $8,840,668.00
  • RNLX $2,221,000.00
  • Revenue This Year
  • AGAE N/A
  • RNLX $48.40
  • Revenue Next Year
  • AGAE N/A
  • RNLX $104.00
  • P/E Ratio
  • AGAE N/A
  • RNLX N/A
  • Revenue Growth
  • AGAE 72.20
  • RNLX N/A
  • 52 Week Low
  • AGAE $0.61
  • RNLX $0.22
  • 52 Week High
  • AGAE $1.57
  • RNLX $3.66
  • Technical
  • Relative Strength Index (RSI)
  • AGAE 60.85
  • RNLX 40.38
  • Support Level
  • AGAE $1.16
  • RNLX $0.28
  • Resistance Level
  • AGAE $1.45
  • RNLX $0.35
  • Average True Range (ATR)
  • AGAE 0.15
  • RNLX 0.04
  • MACD
  • AGAE -0.01
  • RNLX 0.01
  • Stochastic Oscillator
  • AGAE 50.00
  • RNLX 22.90

About AGAE Allied Gaming & Entertainment Inc.

Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.

About RNLX Renalytix plc

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Share on Social Networks: